IR@PKUHSC  > 北京大学第一临床医学院  > 儿科
学科主题临床医学
Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension
He, Bing3; Zhang, Fengwen1; Li, Xueying2; Tang, Chaoshu5,6; Lin, Guosheng4; Du, Junbao1; Jin, Hongfang1
关键词Bosentan Iloprost Meta-analysis Pulmonary arterial hypertension Sildenafil
刊名CIRCULATION JOURNAL
2010-07-01
DOI10.1253/circj.CJ-09-0971
74期:7页:1458-1464
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]INHALED ILOPROST ; DOUBLE-BLIND ; EPOPROSTENOL THERAPY ; BOSENTAN THERAPY ; SILDENAFIL
英文摘要

Background: The aim of the present meta-analysis was to evaluate the efficacy and safety of treating pulmonary arterial hypertension (PAH) with inhaled iloprost, oral bosentan and sildenafil.

Methods and Results: The randomized controlled trials on the 3 drugs and placebo were retrieved from the databases MEDLINE, EMBASE, BIOSIS Previews and CNKI up to August 2009. In total 11 studies and 1,391 patients were selected. Compared with placebo, iloprost, bosentan and sildenafil reduced clinical worsening significantly (odds ratio [OR]=0.33, 95% confidence interval [CI]=0.22-0.49, P<0.00001), improved New York Heart Association/World Health Organization functional class (OR=2.81, 95%CI=1.95-4.03, P<0.00001), increased the 6-min walk test by 33.19m, reduced systolic pulmonary arterial pressure, mean pulmonary arterial pressure and pulmonary vascular resistance, increased the cardiac index by 0.40 L.min(-1).m(-2) and increased the cardiac output by 0.53 L/min. The incidence of serious adverse events was similar in the medication groups and the placebo group (OR=1.09, 95%CI=0.69-1.71, P=0.72). In terms of the clinical worsening and functional class amelioration, insignificant differences were found among iloprost, bosentan and sildenafil, but iloprost had the highest incidence of serious adverse events among the 3 drugs.

Conclusions: Inhaled iloprost and oral bosentan and sildenafil are effective and safe in treating PAH. (Circ J 2010; 74: 1458-1464)

语种英语
WOS记录号WOS:000279366500032
引用统计
被引频次:25[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61522
专题北京大学第一临床医学院_儿科
北京大学基础医学院
北京大学第一临床医学院_医学统计室
作者单位1.Peking Univ, Hosp 1, Dept Stat, Beijing 100034, Peoples R China
2.Minist Educ, Key Lab Mol Cardiol, Beijing, Peoples R China
3.Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China
4.Wuhan Univ, Renmin Hosp, Dept Pediat, Wuhan 430072, Peoples R China
5.Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan 430072, Peoples R China
6.Peking Univ, Hlth Sci Ctr, Dept Physiol & Pathophysiol, Beijing 100034, Peoples R China
推荐引用方式
GB/T 7714
He, Bing,Zhang, Fengwen,Li, Xueying,et al. Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension[J]. CIRCULATION JOURNAL,2010,74(7):1458-1464.
APA He, Bing.,Zhang, Fengwen.,Li, Xueying.,Tang, Chaoshu.,Lin, Guosheng.,...&Jin, Hongfang.(2010).Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension.CIRCULATION JOURNAL,74(7),1458-1464.
MLA He, Bing,et al."Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension".CIRCULATION JOURNAL 74.7(2010):1458-1464.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Meta-Analysis of Ran(2234KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[He, Bing]的文章
[Zhang, Fengwen]的文章
[Li, Xueying]的文章
百度学术
百度学术中相似的文章
[He, Bing]的文章
[Zhang, Fengwen]的文章
[Li, Xueying]的文章
必应学术
必应学术中相似的文章
[He, Bing]的文章
[Zhang, Fengwen]的文章
[Li, Xueying]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。